Cogent Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cogent Biosciences has a total shareholder equity of $422.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $476.1M and $53.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$435.74m |
Equity | US$422.33m |
Total liabilities | US$53.78m |
Total assets | US$476.11m |
Recent financial health updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Recent updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09Financial Position Analysis
Short Term Liabilities: COGT's short term assets ($441.9M) exceed its short term liabilities ($36.7M).
Long Term Liabilities: COGT's short term assets ($441.9M) exceed its long term liabilities ($17.1M).
Debt to Equity History and Analysis
Debt Level: COGT is debt free.
Reducing Debt: COGT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: COGT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if COGT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.